D Wallwiener
Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program
Müller V, Müller L, Janni W, Wimberger P, Jäger B, Pantel K, Riethdorf S, Harbeck N, Fehm T, Hoffmann O, Rübner M, Huober J, Banys-Paluchowski M, Friedl T, Fasching P, Schneeweiss A, Hartkopf A, Wallwiener D, Rack B, Meier-Stiegen F, DETECT study group. Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program. ESMO Open 2021; 6:100299.
25.11.2021Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program
25.11.2021ESMO Open 2021; 6:100299
Müller V, Müller L, Janni W, Wimberger P, Jäger B, Pantel K, Riethdorf S, Harbeck N, Fehm T, Hoffmann O, Rübner M, Huober Jens, Banys-Paluchowski M, Friedl T W P, Fasching P A, Schneeweiss A, Hartkopf A, Wallwiener D, Rack B, Meier-Stiegen F, DETECT study group
Die Zukunft der operativen Gynäkologie
Winder F, Magerle M, Wenzl R, Wallwiener D (2020). Die Zukunft der operativen Gynäkologie. Präsentiert bei: 34. Arlberger Gynäkologielehrgang: Neuerungen, Schwerpunkte und Leitlinien, Zürs am Arlberg
24.01.2020Die Zukunft der operativen Gynäkologie
24.01.202034. Arlberger Gynäkologielehrgang: Neuerungen, Schwerpunkte und Leitlinien
Winder Franziska, Magerle M, Wenzl R, Wallwiener D
Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression
Nitz U, Weiss E, Böhmer S, Kreienberg R, du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Hoffmann G, Augustin D, Möbus V, Gluz O, Huober J, Kreipe H, Kates R, Hartmann A, Erber R, Moustafa Z, Scholz M, Lisboa B, Mohrmann S, Kuhn W. Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression. Ann Oncol 2017; 28:2899.
01.01.2017Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression
01.01.2017Ann Oncol 2017; 28:2899
Nitz U, Weiss E, Böhmer S, Kreienberg R, du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Hoffmann G, Augustin D, Möbus V, Gluz O, Huober Jens, Kreipe H H, Kates R E, Hartmann A, Erber R, Moustafa Z, Scholz M, Lisboa B, Mohrmann S, Kuhn W
Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial
Gluz O, Augustin D, Hoffmann G, Thomssen C, Jänicke F, Kiechle M, Wallwiener D, Kuhn W, Nitz U, Möbus V, Mohrmann S, Liedtke C, Huober J, Peyro-Saint-Paul H, Kates R, Kreipe H, Hartmann A, Pelz E, Erber R, Harbeck N. Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial. Ann Oncol 2016; 27:1035-1040.
18.02.2016Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial
18.02.2016Ann Oncol 2016; 27:1035-1040
Gluz O, Augustin D, Hoffmann G, Thomssen C, Jänicke F, Kiechle M, Wallwiener D, Kuhn W, Nitz U, Möbus V, Mohrmann S, Liedtke C, Huober Jens, Peyro-Saint-Paul H, Kates R E, Kreipe H H, Hartmann A, Pelz E, Erber R, Harbeck N
Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression
Nitz U, Weiss E, Böhmer S, Kreienberg R, du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Hoffmann G, Augustin D, Möbus V, Gluz O, Huober J, Kreipe H, Kates R, Hartmann A, Erber R, Moustafa Z, Scholz M, Lisboa B, Mohrmann S, Kuhn W. Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression. Ann Oncol 2014; 25:1551-7.
14.05.2014Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression
14.05.2014Ann Oncol 2014; 25:1551-7
Nitz U, Weiss E, Böhmer S, Kreienberg R, du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Hoffmann G, Augustin D, Möbus V, Gluz O, Huober Jens, Kreipe H H, Kates R E, Hartmann A, Erber R, Moustafa Z, Scholz M, Lisboa B, Mohrmann S, Kuhn W
Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients
Solomayer E, Wallwiener D, Wackwitz B, Krämer B, Huober J, Becker S, Lück H, Janni W, Hirnle P, Gebauer G, Fehm T. Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients. Ann Oncol 2012; 23:2271-2277.
01.03.2012Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients
01.03.2012Ann Oncol 2012; 23:2271-2277
Solomayer E-F, Wallwiener D, Wackwitz B, Krämer B, Huober Jens, Becker S, Lück H-J, Janni W, Hirnle P, Gebauer G, Fehm T
Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial
Huober J, Nimmrich I, May C, Beckmann M, Baumgärtner A, Kubista E, Ragosch V, Azim H, Paepke S, Reimer T, Thomssen C, Wallwiener D, Petruzelka L, Barsoum M, Fasching P, Harbeck N. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial. Breast 2011; 21:27-33.
08.09.2011Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial
08.09.2011Breast 2011; 21:27-33
Huober Jens, Nimmrich I, May C, Beckmann M W, Baumgärtner A K, Kubista E, Ragosch V, Azim H A, Paepke S, Reimer T, Thomssen C, Wallwiener D, Petruzelka L, Barsoum M, Fasching P A, Harbeck N
Stage I carcinoma of the Bartholin's gland managed with the detection of inguinal and pelvic sentinel lymph node
Kraemer B, Guengoer E, Solomayer E, Wallwiener D, Hornung R. Stage I carcinoma of the Bartholin's gland managed with the detection of inguinal and pelvic sentinel lymph node. Gynecol Oncol 2009; 114:373-374.
01.08.2009Stage I carcinoma of the Bartholin's gland managed with the detection of inguinal and pelvic sentinel lymph node
01.08.2009Gynecol Oncol 2009; 114:373-374
Kraemer B, Guengoer E, Solomayer E F, Wallwiener D, Hornung René
Salvage chemotherapy for metastatic breast cancer: results of a phase II study with bendamustine
Reichmann U, Bokemeyer C, Wallwiener D, Bamberg M, Huober J. Salvage chemotherapy for metastatic breast cancer: results of a phase II study with bendamustine. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007; 18:1981-4.
01.12.2007Salvage chemotherapy for metastatic breast cancer: results of a phase II study with bendamustine
01.12.2007Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007; 18:1981-4
Reichmann U, Bokemeyer C, Wallwiener D, Bamberg M, Huober Jens
Management of late recurrence of a low-grade endometrial stromal sarcoma (LGESS): treatment with letrozole
Krauss K, Bachmann C, Hartmann J, Siegmann K, Sotlar K, Wallwiener D, Huober J. Management of late recurrence of a low-grade endometrial stromal sarcoma (LGESS): treatment with letrozole. Anticancer research 2007; 27:3477-80.
01.01.2007Management of late recurrence of a low-grade endometrial stromal sarcoma (LGESS): treatment with letrozole
01.01.2007Anticancer research 2007; 27:3477-80
Krauss K, Bachmann C, Hartmann J T, Siegmann K, Sotlar K, Wallwiener D, Huober Jens
[Adjuvant therapy with trastuzumab (Herceptin) in primary breast cancer]
Huober J, Jackisch C, Untch M, Möbus V, Wallwiener D, Kaufmann M, Minkwitz G. [Adjuvant therapy with trastuzumab (Herceptin) in primary breast cancer]. Zentralblatt für Gynäkologie 2006; 128:30-7.
01.02.2006[Adjuvant therapy with trastuzumab (Herceptin) in primary breast cancer]
01.02.2006Zentralblatt für Gynäkologie 2006; 128:30-7
Huober Jens, Jackisch C, Untch M, Möbus V, Wallwiener D, Kaufmann M, Minkwitz G
Neue Aspekte der adjuvanten Theraphie beim Mammakarzinom - die Aromatasehemmer
Krauss K, Wallwiener D, Huober J. Neue Aspekte der adjuvanten Theraphie beim Mammakarzinom - die Aromatasehemmer. Geburtsh Frauenheilk 2005; 65:803-805.
01.01.2005Neue Aspekte der adjuvanten Theraphie beim Mammakarzinom - die Aromatasehemmer
01.01.2005Geburtsh Frauenheilk 2005; 65:803-805
Krauss K, Wallwiener D, Huober Jens
Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I/II study
Schneeweiss A, Wallwiener D, Hamerla R, Solomayer E, Krauss K, Beldermann F, Rudlowski C, von Fournier D, Sinn H, Huober J, Bastert G. Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I/II study. European journal of cancer (Oxford, England : 1990) 2004; 40:2432-8.
01.11.2004Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I/II study
01.11.2004European journal of cancer (Oxford, England : 1990) 2004; 40:2432-8
Schneeweiss A, Wallwiener D, Hamerla R, Solomayer E, Krauss K, Beldermann F, Rudlowski C, von Fournier D, Sinn H-P, Huober Jens, Bastert G
Value of positron emission tomography scan in staging cancers, and an unusual presentation of acute myeloid leukemia. Case 2. Detection of an appendiceal carcinoma by whole-body positron emission tomography after Caesarean section
Krauss K, Aydeniz B, Dohmen B, Wehrmann M, Wallwiener D, Huober J. Value of positron emission tomography scan in staging cancers, and an unusual presentation of acute myeloid leukemia. Case 2. Detection of an appendiceal carcinoma by whole-body positron emission tomography after Caesarean section. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004; 22:2966-8.
15.07.2004Value of positron emission tomography scan in staging cancers, and an unusual presentation of acute myeloid leukemia. Case 2. Detection of an appendiceal carcinoma by whole-body positron emission tomography after Caesarean section
15.07.2004Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004; 22:2966-8
Krauss K, Aydeniz B, Dohmen B M, Wehrmann M, Wallwiener D, Huober Jens
Inhibition of human breast cancer cell proliferation with estradiol metabolites is as effective as with tamoxifen
Seeger H, Huober J, Wallwiener D, Mueck A. Inhibition of human breast cancer cell proliferation with estradiol metabolites is as effective as with tamoxifen. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 2004; 36:277-80.
01.05.2004Inhibition of human breast cancer cell proliferation with estradiol metabolites is as effective as with tamoxifen
01.05.2004Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 2004; 36:277-80
Seeger H, Huober Jens, Wallwiener D, Mueck A O
Is the combination with 2-methoxyestradiol able to reduce the dosages of chemotherapeutices in the treatment of human ovarian cancer? Preliminary in vitro investigations
Mueck A, Seeger H, Wallwiener D, Huober J. Is the combination with 2-methoxyestradiol able to reduce the dosages of chemotherapeutices in the treatment of human ovarian cancer? Preliminary in vitro investigations. European journal of gynaecological oncology 2004; 25:699-701.
01.01.2004Is the combination with 2-methoxyestradiol able to reduce the dosages of chemotherapeutices in the treatment of human ovarian cancer? Preliminary in vitro investigations
01.01.2004European journal of gynaecological oncology 2004; 25:699-701
Mueck A O, Seeger H, Wallwiener D, Huober Jens
Aktueller Stellenwert des Ultraschalls in der Mammadiagnostik
Krainick-Strobel U, Bergmann A, Huober J, Wallwiener D. Aktueller Stellenwert des Ultraschalls in der Mammadiagnostik. Geburtsh Frauenheilk 2004; 64:632-633.
01.01.2004Aktueller Stellenwert des Ultraschalls in der Mammadiagnostik
01.01.2004Geburtsh Frauenheilk 2004; 64:632-633
Krainick-Strobel U, Bergmann A, Huober Jens, Wallwiener D
Effect of tamoxifen and 2-methoxyestradiol alone and in combination on human breast cancer cell proliferation
Seeger H, Diesing D, Gückel B, Wallwiener D, Mueck A, Huober J. Effect of tamoxifen and 2-methoxyestradiol alone and in combination on human breast cancer cell proliferation. The Journal of steroid biochemistry and molecular biology 2003; 84:255-7.
01.02.2003Effect of tamoxifen and 2-methoxyestradiol alone and in combination on human breast cancer cell proliferation
01.02.2003The Journal of steroid biochemistry and molecular biology 2003; 84:255-7
Seeger H, Diesing D, Gückel B, Wallwiener D, Mueck A O, Huober Jens
St. Gallen 2003 - Was tun?
Wallwiener D, Huober J. St. Gallen 2003 - Was tun?. Frauenarzt 2003; 44:516-517.
01.01.2003St. Gallen 2003 - Was tun?
01.01.2003Frauenarzt 2003; 44:516-517
Wallwiener D, Huober Jens
[CD80-modified tumor cell lines: implications for cell-based vaccinations in breast cancer patients]
Gückel B, Stumm S, Kayser S, Rentzsch C, Gruber I, Marmé A, Huober J, Meuer S, Wallwiener D. [CD80-modified tumor cell lines: implications for cell-based vaccinations in breast cancer patients]. Zentralblatt für Gynäkologie 2002; 124:566-73.
01.12.2002[CD80-modified tumor cell lines: implications for cell-based vaccinations in breast cancer patients]
01.12.2002Zentralblatt für Gynäkologie 2002; 124:566-73
Gückel B, Stumm S, Kayser S, Rentzsch C, Gruber I, Marmé A, Huober Jens, Meuer S C, Wallwiener D